TEL AVIV, Israel, March 01, 2016 -- Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced corporate presentations at the upcoming 28th Annual ROTH Conference and the Barclays Global Healthcare Conference.
| 28th Annual ROTH Conference | |
| Date: | Monday, March 14 |
| Time: | 1:00pm Pacific Time |
| Location: | Ritz Carlton, Laguna Niguel, California |
| Presenter: | David Baker, Chief Commercial Officer |
| Barclays Global Healthcare Conference | |
| Date: | Thursday, March 17 |
| Time: | 10:45am Eastern Time |
| Location: | Loews Miami Beach Hotel, Miami, Florida |
| Presenter: | Dr. Yaron Daniely, President & Chief Executive Officer |
| Webcast: | https://cc.talkpoint.com/barc002/031516a_ae/?entity=72_U2Q8T5Q |
About Alcobra Ltd.
Alcobra Ltd. is an emerging pharmaceutical company primarily focused on the development and commercialization of a proprietary drug candidate, MDX, to treat cognitive disorders including ADHD and FXS. For more information please visit the Company's website, www.alcobra-pharma.com, the content of which is not incorporated herein by reference.
U.S. Investor Contacts LifeSci Advisors, LLC Michael Rice 646-597-6979 mrice@lifesciadvisors.com Media Inquiries Sam Brown, Inc. Mike Beyer 773-463-4211 mikebeyer@sambrown.com Israel Investor Contact: Alcobra Investor Relations Debbie Kaye +972-72 2204661 debbie@alcobra-pharma.com
